Sapiens appoints Jan Keltjens as President and CEO
(Thomson Reuters ONE) -
Sapiens Steering Brain Stimulation BV /
Sapiens appoints Jan Keltjens as President and CEO
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Munich, Germany, and Eindhoven, the Netherlands, October 21, 2013 - Sapiens
Steering Brain Stimulation (Sapiens), a medical device company pioneering brain
stimulation products incorporating steerable stimulation, today announced that
the Advisory Board has appointed Jan C. M. Keltjens as the new President and CEO
of the Company, effective October 21, 2013.
Jan Keltjens has a strong track record in the medical device sector and over 30
years of management experience. Recently, he was Chairman, President and CEO of
Endosense SA, Geneva, Switzerland, which was acquired by St. Jude Medical in
August 2013. Prior to this, he worked as CEO and/or Chairman in a number of
medical device companies worldwide, including CryoCath Technologies Inc.,
Montreal, Canada (acquired in 2008 by Medtronic), AngioDynamics Inc., Albany,
New York, USA, and Surpass Medical Ltd., Tel Aviv, Israel/Sunrise, Florida, USA
(acquired in 2012 by Stryker). From 1995 to 2007 he was Vice President and later
Worldwide General Manager Neurovascular at Cordis, a Johnson & Johnson company,
in the Netherlands, Belgium and Florida, USA. Jan Keltjens graduated with a
Master of Science in Physics from the University of Eindhoven and subsequently
started his career at the Unilever Research Laboratory in Vlaardingen, the
Netherlands.
Hans Barella, Chairman of the Advisory Board, commented: "We are very happy to
have appointed Jan Keltjens as the President and CEO for Sapiens. With his
excellent skills and expertise in combination with his international experience
in commercializing breakthrough products, he is ideally suited to lead the
Company towards launching its first products and subsequent commercial
successes. I would like to thank Sjaak Deckers for his past three years of
leadership and shaping the Company for a successful future. Sjaak was not only
the co-founder of Sapiens, but also successfully raised the initial financing
for Sapiens and reached positive results with 'FAME', the world's first intra-
operative clinical study demonstrating steerable brain stimulation."
Jan Keltjens, President and CEO, added: "Sapiens is a very exciting company that
I know well from my position on the Advisory Board since February 2012. I am
looking forward to working with the co-founders, our Advisory Board and the
strong Sapiens team, including Sjaak who will continue to serve in a senior
leadership role. Deep brain stimulation (DBS) is a rapidly growing therapy to
treat neurological diseases such as Parkinson's disease, essential tremor and
dystonia. The innovations being developed by Sapiens will allow more patients to
benefit from DBS while minimizing the side-effects and reducing time and
resources for the complex procedure. We look forward to bringing this technology
to patients who suffer from such potentially debilitating diseases."
About Sapiens Steering Brain Stimulation
Sapiens Steering Brain Stimulation is an emerging medical device company with a
mission to bring the innovative concept of Steering Deep Brain Stimulation (DBS)
to more patients who can benefit from this advanced treatment for degenerative
or functional brain disorders, such as Parkinson's disease, dystonia and other
currently emerging indications.
Sapiens' ambition is to improve the therapeutic efficacy of DBS, to shorten and
simplify the clinical procedure, and to improve patient comfort. Sapiens' high-
resolution probe enables the reduction of stimulation-induced side-effects by
precisely shaping the stimulation field to the intended target area. The
SureSuite® products, SurePlan®, SurePlace® and SureTune®, provide an integrated,
image-based solution for planning and programming an optimal DBS treatment.
SureStim-1®, the Sapiens implant, is MRI-conditionally safe, and controls the
steering.
With offices in Eindhoven, the Netherlands and Munich, Germany, Sapiens was
founded in 2011. The Company is a spin-out of Royal Philips, and is backed by
Wellington Partners, Edmond de Rothschild Investment Partners, Life Sciences
Partners (LSP), the Wellcome Trust and INKEF Capital. Additionally, the Michael
J Fox Foundation and the European Union Framework Program VII provide support.
Sapiens' Steering Brain Stimulation probe, implant and image-guided programming
are all based on patented technologies.
For more information please visit www.sapiensneuro.com.
Contact:
Jan Keltjens, CEO
Sapiens Steering Brain Stimulation,
High Tech Campus 41,
5656 AE Eindhoven, the Netherlands
Tel. +31 40 8002100
info(at)sapiensneuro.com
Press release (PDF):
http://hugin.info/147880/R/1736893/582186.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Sapiens Steering Brain Stimulation BV via Thomson Reuters ONE
[HUG#1736893]
Unternehmensinformation / Kurzprofil:
Datum: 21.10.2013 - 12:00 Uhr
Sprache: Deutsch
News-ID 307628
Anzahl Zeichen: 5940
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 154 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sapiens appoints Jan Keltjens as President and CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
Sapiens Steering Brain Stimulation BV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
